Abstract
Non-alcoholic fatty liver disease (NAFLD) is common in obesity. However, weight reduction alone does not prevent the progression of NAFLD to end-stage disease associated with the development of cirrhosis and liver disease. In a previous experiment, 50% ethanol extract ofAcanthopanax senticosus stem bark (ASSB) was found to reduce body weight and insulin resistance in high fat diet-induced hyperglycemic and hyperlipidemic ICR mice. To evaluate the anti-steatosis action of ASSB, insulin-resistant ob/ob mice with fatty livers were treated with ASSB ethanol extract for an 8 week-period. ASSB ethanol extract reversed the hepatomegaly, as evident in reduction of % liver weight/body weight ratio. ASSB ethanol extract also specifically lowered circulating glucose and lipids, and enhanced insulin action in the liver. These changes culminated in inhibition of triglyceride synthesis in non-adipose tissues including liver and skeletal muscle. Gene expression studies confirmed reductions in glucose 6-phosphatase and lipogenic enzymes in the liver. These results demonstrate that ASSB ethanol extract is an effective treatment for insulin resistance and hepatic steatosis in ob/ob mice by decreasing hepatic lipid synthesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Angulo, P. Nonalcoholic fatty liver disease.New Engl. J. Med., 346, 1221–1231 (2002).
Chomczynski, P. and Sacchi, N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.Anal. Biochem. 162, 156–159 (1987).
Cohen, P., Miyazaki, M., Socci, N. D., Hagge-Greenberg, A., Liedtke, W., Soukas, A. A., Sharma, R., Hudgins, L. C., Ntambi, J. M., and Friedman, J. M., Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss.Science, 297, 240–243 (2002).
Cohen, P., Zhao, C., Cai, X., Montez, J. M., Rohani, S. C., Feinstein, P., Mombaerts, P., and Friedman, J. M., Selective deletion of leptin receptor in neurons leads to obesity.J. Clin. Invest., 108, 1113–1121 (2001).
Cusi, K., Consol, A., and DeFronzo, R. A., Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.J. Clin. Endocr. and Metab. 81, 4059–4067 (1996).
Davies, G. F., Khandelwal, R. L., Wu, L., Juurlink, B. H., and Roesler, W. J., Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism.Biochem Pharmacol., 62, 1071–1079 (2001).
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., and Parks, E. J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with NAFLD.J. Clin. Invest., 115, 1343–1351 (2005).
Hookman, P. and Barkin, J. S., Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.Am. J. Gastroenterol., 98, 2093–2097 (2002).
Liang, C. P. and Tall, A. R., Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver.J. Biol. Chem., 276, 49066–49076 (2001).
Lin, H. Z., Yang, S. Q., Kujhada, F., Ronnet, G., and Diehl, A. M., Metformin reverses nonalcoholic fatty liver disease in obese leptin-deficient mice.Nat. Med., 6, 998–1003 (2000).
Manco, M., Calvani, M., and Mingrone, G., Effects of dietary fatty acids on insulin sensitivity and secretion.Diabetes. Obes. Metab., 6, 402–413 (2004).
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Zoli, M., and Melchionda, N., Metformin in non-alcoholic steatohepatitis.Lancet., 358, 893–894 (2001).
Matthews, D. R., Hosker, J. P., Rudenky, A. S., Naylor, B. A., Treacher, D. F., and Turner, R. C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man.Diabetologia, 28, 412–419 (1985).
Mithieux, G., New knowledge regarding glucose-6-phosphatase gene and protein and their roles in the regulation of glucose metabolism.Eur. J. Endocr., 136, 137–145 (1997).
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., and Bacon, B. R., Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.Hepatology, 38, 1008–1017 (2003).
Nishioka, S., Kinoshita, H., Takeda, H., and Okano, G., Phenolic compounds from the stem bark of Acanthopanax senticosus and their pharmacological effect in chronic swimming stressed rats.Chem. Pharm Bull., 38, 1763–1765 (1990).
Schwarz, J. M., Linfoot, P., Date, D. and Aghajanian, K., Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high fat, low carbohydrate and low fat, high catbohydrate isoenergetic diets.Am. J. Clin. Nutr., 77, 43–50 (2003).
Shimomura, I., Bashmakov, Y., and Horton, J. D., Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus.J. Biol. Chem. 274, 30028–30032 (1999).
Trinder, P., Determination of blood glucose using an oxidaseperoxidase system with a non-carcinogenic chromogen.J. Clin. Pathol., 22, 158–161 (1969).
Tolman, K. G., Fonseca, V., Tan, M. H., and Dalpiaz, A., Narative review: hepatobiliary disease in type 2 diabetes mellitus.Annu. Intern. Med., 141, 946–956 (2004).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Park, S.H., Lee, S.G., Kang, S.K. et al. Acanthopanax senticosus reverses fatty liver disease and hyperglycemia in ob/ob mice. Arch Pharm Res 29, 768–776 (2006). https://doi.org/10.1007/BF02974078
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02974078